Welcome to our new website. We have rebranded from Lamepro to Pharmanovia Benelux
Global site
Pharmanovia appoints Dr Béchir BEN HADJ YAHIA as Global Head of Medical Affairs
BASILDON, UK, 7 October 2026 Pharmanovia, the global specialty pharmaceutical company, today announced the appointment of…
More informationIMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion
For business and trade media only Positive opinion for Senaparib, as a Potential First-Line Maintenance Treatment…
More informationPharmanovia appoints Julia Schüssler as Chief People and Culture Officer and John Parsons as General Counsel to support next phase of growth
FOR IMMEDIATE RELEASE – BASILDON, UK, 17 JUNE 2026 Pharmanovia, a global specialty pharmaceutical company, has…
More informationPharmanovia announces a first-in-class drug therapy treatment
PRESS RELEASE – FOR TRADE AND BUSINESS MEDIA ONLY PHARMANOVIA ANNOUNCES LAUNCH OF KORJUNY (CATUMAXOMAB) IN…
More informationPharmanovia appoints Stephan Eder as Chief Executive Officer
For immediate release, 1st October 2025, Basildon, UK: Pharmanovia today announced the appointment of Stephan Eder as…
More informationPharmanovia Leadership Update
FOR IMMEDIATE RELEASE – BASILDON, UK, 10th APRIL 2025 Pharmanovia, a global pharmaceutical company that commercialises…
More informationPharmanovia acquires exclusive rights to novel antipsychotic treatment
BASILDON, UK, 1st April 2025 Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises,…
More informationPharmanovia announces exclusive distribution agreement with Er-Kim for Sunosi® in Eastern Europe
PRESS RELEASE – FOR TRADE AND BUSINESS MEDIA ONLY Basildon, UK – 21 February 2025 Pharmanovia,…
More informationLindis Biotech and Pharmanovia announce European marketing authorisation approval for a first-in-class treatment
PRESS RELEASE – FOR TRADE AND BUSINESS MEDIA ONLY MUNICH, GERMANY, AND BASILDON, UK, 13 February…
More informationPharmanovia signs in-licensing deal for novel osteoporosis treatment with Radius Health
BASILDON, UK, 02 January 2025 Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises,…
More informationPharmanovia announces submission of Paediatric Investigational Plan (PIP) for elamipretide to the medicines and healthcare product regulatory agency (MHRA)
PRESS RELEASE – FOR TRADE, MEDICAL AND BUSINESS MEDIA ONLY BASILDON, UK, 20 December 2024 Pharmanovia,…
More informationPharmanovia signs novel biologic in-licensing agreement
PRESS RELEASE – FOR TRADE, MEDICAL AND BUSINESS MEDIA ONLY BASILDON, UK, 19 November 2024 Pharmanovia,…
More informationPharmanovia acquires exclusive rights to treatment for Parkinson’s disease
PRESS RELEASE – FOR TRADE, BUSINESS AND MEDICAL MEDIA ONLY BASILDON, UK, Monday 7 October 2024 …
More informationNew Pharmanovia study results reveal chloral hydrate noticeably improves severe insomnia within two weeks
FOR MEDICAL TRADE AND BUSINESS MEDIA ONLY BASILDON, UK, 30 September 2024 Pharmanovia, a global pharmaceutical…
More informationPharmanovia partners with Echo Therapeutics for promotional activities in Australia
For immediate release, 20TH May, 2024 Pharmanovia, the lifecycle management company, has today announced that it…
More information